EMBA at China Europe International Business School (CEIBS);

With more than 30 years of experience in manufacturing, financial insurance, internet health, venture capital and other fields.

Be responsible for Consun drug strategy development direction. Professor Zhu has over 50 years of experience in medical research.He was the Director and doctoral supervisor of National Standardization Laboratory for Chinese Herbal Pharmacology (國(guó)家規(guī)范化中藥藥理實(shí)驗(yàn)室). 

Professor Barratt is the Mayer Professor of Renal Medicine and Consultant Nephrologist of University of Leicester and leads the Mayer IgA Nephropathy Research Group at the University of Leicester. He is also the IgA nephropathy Rare Disease Group lead for the United Kingdom National Registry of Rare Kidney Diseases (RaDaR) and the convener of the steering committee of The International IgA Nephropathy Network. Professor Barratt regularly provides advice and guidance to companies submitting applications to the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). He leads the IgAN group updating the international KIDGO guidelines on the clinical management of glomerular disease. Professor Barratt is also an editorial board member of authoritative journals, such as “Kidney International” and “Clinical Journal of the American Society of Nephrology”, and has made outstanding contributions to the diagnosis and treatment of kidney disease and the development of new drugs.